Large Volume Parenteral (LVP) Market Report 2026

The large volume parenteral (lvp) market size has grown strongly in recent years. It will grow from $13.53 billion in 2025 to $14.76 billion in 2026 at a compound annual growth rate (CAGR) of 9.1%. The growth in the historic period can be attributed to rising hospitalization rates, growth in intravenous fluid therapy usage, increasing surgical procedures, expansion of critical care infrastructure, growth in infectious disease treatment.

The large volume parenteral (lvp) market size is expected to see strong growth in the next few years. It will grow to $21.37 billion in 2030 at a compound annual growth rate (CAGR) of 9.7%. The growth in the forecast period can be attributed to aging population growth, rising prevalence of chronic diseases, increasing demand for parenteral nutrition, expansion of healthcare infrastructure in emerging markets, growth in emergency and trauma care services. Major trends in the forecast period include growing demand for non-pvc and eco-friendly lvp packaging, expansion of ready-to-use and premixed infusion solutions, increasing focus on sterility and contamination control, rising use of lvps in critical care and emergency medicine, growth in hospital-based infusion therapy volumes.

The increasing prevalence of chronic diseases is expected to drive the growth of the large-volume parenteral market in the coming years. Chronic diseases are illnesses or conditions that typically persist for three months or longer and may worsen over time. The rise in chronic diseases is primarily influenced by tobacco use, exposure to secondhand smoke, and poor nutrition. Patients with these conditions often require an appropriate balance of essential nutrients to maintain strength, and the parenteral route of administration ensures accurate pharmaceutical dosing, as most of the drug is directly absorbed into the bloodstream, bypassing the digestive system. For example, in September 2023, according to the World Health Organization, a Switzerland-based specialized agency of the United Nations, there were 41 million deaths globally each year, accounting for 74% of all deaths caused by non-communicable diseases (NCDs) or chronic diseases. Consequently, the rising prevalence of chronic diseases supports the growth of the large-volume parenteral market.

The rising healthcare expenditure is expected to drive the growth of the large-volume parenteral market in the coming years. Healthcare expenditure refers to the increasing amount of money allocated to healthcare services and related activities, including health research and public health initiatives. Higher healthcare spending is often linked to the development and expansion of healthcare infrastructure. This encompasses the construction of new hospitals, clinics, and other medical facilities. With enhanced infrastructure, there is a greater capacity to deliver medical services, thereby boosting the demand for LVP solutions. For example, in April 2025, the American Medical Association, a U.S.-based professional association, reported that health spending in the U.S. increased by 7.5% in 2023, reaching $4.9 trillion, or $14,570 per person, representing a significant rise compared to the 4.6% growth recorded in 2022. Consequently, the rising healthcare expenditure supports the growth of the large-volume parenteral market.

Major companies operating in the large volume parenteral (LVP) market are concentrating on developing advanced infusion‑device technologies, such as intelligent large‑volume infusion pumps, to address the growing demand for safer, more automated, and connected intravenous therapy driven by the increase in hospital-based infusion services, remote patient monitoring, and the movement toward standardized, error‑resistant medication administration. An intelligent large‑volume infusion pump is a device designed to deliver high-volume IV fluids (LVP) with integrated dose‑error reduction software, connectivity for smart drug libraries, and alarm management. Unlike traditional infusion pumps, which rely primarily on manual programming and limited automation, these next-generation pumps help prevent dosing errors, reduce workflow burdens, and integrate with hospital IT systems. For example, in April 2024, Baxter International Inc., a US-based pharmaceutical and medical-device company, received U.S. FDA clearance for its Novum IQ Large‑Volume Infusion Pump with Dose IQ smart-dose software. The device supports high-rate fluid delivery, including large-volume infusions, provides safety features such as drug library integration to minimize dosing errors, and allows connectivity to hospital electronic medical records and smart monitoring platforms. By enabling safe, automated, and worry-free infusion of large volumes, the Novum IQ pump assists healthcare providers in improving infusion accuracy, lowering the risk of dosing mistakes, and streamlining high‑volume IV therapy workflows.

Major companies operating in the large volume parenteral (lvp) market are Pfizer Inc., Fresenius Kabi AG, Abbott Laboratories Inc., Otsuka Holdings Co. Ltd., Baxter International Inc., B. Braun Melsungen AG, Grifols S.A., Cipla Limited, ICU Medical Inc., Biocon Limited, Sichuan Kelun Pharmaceutical Co. Ltd., Alembic Pharmaceuticals Limited, Cadila Healthcare Ltd., Gland Pharma Limited, Akums Drugs & Pharmaceuticals Ltd., Beximco Pharmaceutical Ltd., Taj Pharmaceuticals Limited, Albert David Ltd., Amanta Healthcare Ltd., Unique Pharmaceutical Laboratories Ltd., Ahlcon Parenterals India Ltd., Parenteral Drugs Limited, Abaris Healthcare Pvt. Ltd., BML Parenteral Drugs, Denis Chem Lab Ltd., Pentagon Labs Ltd., DJ Labs Pvt. Ltd., Higgs Healthcare.

North America was the largest region in the large volume parenteral (LVP) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the large volume parenteral (lvp) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the large volume parenteral (lvp) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have moderately impacted the large volume parenteral market by increasing costs of imported raw materials, packaging components, and manufacturing equipment. Product segments such as non-pvc soft bags, plastic containers, and glass bottles are most affected, particularly in asia-pacific and north america where cross-border sourcing is common. Higher production costs have pressured pricing for hospitals and medical centers. However, tariffs have also encouraged local manufacturing, regional sourcing of packaging materials, and long-term strengthening of domestic lvp supply chains.

The large volume parenteral (lvp) market research report is one of a series of new reports that provides large volume parenteral (lvp) market statistics, including large volume parenteral (lvp) industry global market size, regional shares, competitors with a large volume parenteral (lvp) market share, detailed large volume parenteral (lvp) market segments, market trends and opportunities, and any further data you may need to thrive in the large volume parenteral (lvp) industry. This large volume parenteral (lvp) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Large volume parenterals (LVPs) are sterile intravenous solutions with a volume of 100 ml or more that are terminally sterilized using heat. They are administered through intravenous infusion to deliver hydration, nutrition, and medications.

The primary types of large-volume parenterals (LVPs) include soft bag LVPs, plastic bag LVPs, and glass bottle LVPs. Soft bag LVPs are flexible containers filled with sterilized IV solutions and are widely used in healthcare settings to supply fluids and drugs to patients. These products are available in volumes ranging from 100 ml-250 ml, 250 ml-500 ml, 500 ml-1000 ml, 1000 ml-2000 ml, and 2000 ml and above, and are utilized for basic infusion, therapeutic infusion, and nutritional infusion. The key end users include hospitals, medical centers, and other healthcare facilities.

The large-volume parenteral (LVP) market consists of sales of sterile intravenous solutions, peritoneal dialysis solutions, plasma substitutes, and sterile powders. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.